Revolution Medicines Shows Major Advances in KRAS Inhibitors at AACR

Revolution Medicines' latest data demonstrate a significant leap in targeting KRAS mutations, a notoriously difficult cancer target. The doubled survival rate in second-line pancreatic cancer highlights the drug's potential clinical impact. The introduction of RM-055 suggests a promising new avenue for catalytic inhibitors, potentially broadening treatment options.